Xerecept enters Phase III for brain swelling
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neurobiological Technologies initiates Phase III development of its synthetic human corticotropin-releasing factor Xerecept as a treatment for peritumoral cerebral edema, the firm announces April 20. The program will include two concurrent studies. The first study, in chronically treated patients, has begun, with a primary endpoint of a 50% reduction in steroid use following three weeks of treatment. The second study will be in the acute setting. Xerecept has orphan drug status for the condition...